Adeno-associated virus (AAV)-U7–mediated skipping of dystrophin-exon-23 restores dystrophin expression and muscle function in the mdx mouse model of Duchenne muscular dystrophy. Soluble activin receptor IIB (sActRIIB-Fc) inhibits signaling of myostatin and homologous molecules and increases muscle mass and function of wild-type and mdx mice. We hypothesized that combined treatment with AAV-U7 and sActRIIB-Fc may synergistically improve mdx muscle function. Bioactivity of sActRIIB-Fc on skeletal muscle was first demonstrated in wild-type mice. In mdx mice we show that AAV-U7–mediated dystrophin restoration improved specific muscle force and resistance to eccentric contractions when applied alone. Treatment of mdx mice with sActRIIB-Fc increased body weight, muscle mass and myofiber size, but had little effect on muscle function. Combined treatment stimulated muscle growth comparable to the effect of sActRIIB-Fc alone and dystrophin rescue was similar to AAV-U7 alone. Moreover, combined treatment improved maximal tetanic force and the resistance to eccentric contraction to similar extent as AAV-U7 alone. In conclusion, combination of dystrophin exon skipping with sActRIIB-Fc brings together benefits of each treatment; however, we failed to evidence a clear synergistic effect on mdx muscle function.
Get full access to this article
View all access options for this article.
References
1.
Aartsma-RusA.2010. Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy. RNA Biol., 7:453–461.
2.
AmthorH., OttoA., VulinA.et al.2009. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc. Natl. Acad. Sci. U. S. A., 106:7479–7484.
3.
BenchaouirR., MeregalliM., FariniA.et al.2007. Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell., 1:646–657.
4.
BlaauwB., CanatoM., AgateaL.et al.2009. Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J., 23:3896–3905.
5.
BlaauwB., AgateaL., TonioloL.et al.2010. Eccentric contractions lead to myofibrillar dysfunction in muscular dystrophy. J. Appl. Physiol., 108:105–111.
6.
BlakeD.J., WeirA., NeweyS.E., DaviesK.E.2002. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev., 82:291–329.
7.
BodineS.C., StittT.N., GonzalezM.et al.2001. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol., 3:1014–1019.
8.
BogdanovichS., KragT.O., BartonE.R.et al.2002. Functional improvement of dystrophic muscle by myostatin blockade. Nature., 420:418–421.
CirakS., Arechavala-GomezaV., GuglieriM.et al.2011. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet., 378:595–605.
11.
ClopA., MarcqF., TakedaH.et al.2006. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet., 38:813–818.
12.
De AngelisF.G., SthandierO., BerarducciB.et al.2002. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48–50 DMD cells. Proc. Natl. Acad. Sci. U. S. A., 99:9456–9461.
13.
DeconinckN., TinsleyJ., DeB.F.et al.1997. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat. Med., 3:1216–1221.
14.
DelloRussoC., CrawfordR.W.et al.2001. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J. Muscle Res. Cell Motil., 22:467–475.
15.
DentiM.A., RosaA., D'AntonaG.et al.2006. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc. Natl. Acad. Sci. U. S. A., 103:3758–3763.
16.
DentiM.A., IncittiT., SthandierO.et al.2008. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum. Gene Ther., 19:601–608.
17.
DumonceauxJ., MarieS., BeleyC.et al.2010. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol. Ther., 18:881–887.
18.
FosterH., SharpP.S., AthanasopoulosT.et al.2008. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther., 16:1825–1832.
19.
GeorgeC.C., BruemmerK., SestiJ.et al.2011. Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle Nerve., 43:694–699.
20.
GoemansN.M., TuliniusM., van den AkkerJ.T.et al.2011. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med., 364:1513–1522.
21.
GoyenvalleA., VulinA., FougerousseF.et al.2004. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science., 306:1796–1799.
22.
GrobetL., MartinL.J., PonceletD.et al.1997. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat. Genet., 17:71–74.
23.
HaidetA.M., RizoL., HandyC.et al.2008. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc. Natl. Acad. Sci. U. S. A., 105:4318–4322.
24.
HeemskerkH., de WinterC., van KuikPet al.2010. Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol. Ther., 18:1210–1217.
25.
HobbsS., JitrapakdeeS., WallaceJ.C.1998. Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins. Biochem. Biophys. Res. Commun., 252:368–372.
26.
HulmiJ.J., SilvennoinenM., LehtiM.et al.2012. Altered REDD1, myostatin, and Akt/mTOR/FoxO/MAPK signaling in streptozotocin-induced diabetic muscle atrophy. Am. J. Physiol Endocrinol. Metab., 302:E307–E315.
27.
Kaivo-OjaN., BondestamJ., KamarainenM.et al.2003. Growth differentiation factor-9 induces Smad2 activation and inhibin B production in cultured human granulosa-luteal cells. J. Clin. Endocrinol. Metab., 88:755–762.
28.
KinaliM., Rechavala-GomezaV., FengL.et al.2009. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol., 8:918–928.
29.
LawlorM.W., ReadB.P., EdelsteinR.et al.2011. Inhibition of activin receptor type IIb increases strength and lifespan in myotubularin-deficient mice. Am. J. Pathol., 178:784–793.
30.
LeeS.J., McPherronA.C.2001. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. U. S. A., 98:9306–9311.
31.
LeeS.J., ReedL.A., DaviesM.V.et al.2005. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc. Natl. Acad. Sci. U. S. A., 102:18117–18122.
32.
LorainS., GrossD.A., GoyenvalleA.et al.2008. Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Mol. Ther., 16:541–547.
33.
LuQ.L., MannC.J., LouF.et al.2003. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med., 9:1009–1014.
34.
LuQ.L., RabinowitzA., ChenY.C.et al.2005. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. Sci. U. S. A., 102:198–203.
35.
MannC.J., HoneymanK., ChengA.J.et al.2001. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. U. S. A., 98:42–47.
36.
McPherronA.C., LawlerA.M., LeeS.J.1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387:83–90.
37.
MorineK.J., BishL.T., SelsbyJ.T.et al.2010. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve, 42:722–730.
38.
MorrisonB.M., LacheyJ.L., WarsingL.C.et al.2009. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol., 217:258–268.
39.
MosherD.S., QuignonP., BustamanteC.D.et al.2007. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS. Genet., 3:e79.
40.
MouiselE., VignaudA., HourdeC.et al.2010. Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18–24-month-old) dystrophic mdx mice. Muscle Nerve, 41:809–818.
41.
NakataniM., TakeharaY., SuginoH.et al.2008. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J., 22:477–487.
42.
Pietri-RouxelF., GentilC., VassilopoulosS.et al.2010. DHPR alpha1S subunit controls skeletal muscle mass and morphogenesis. EMBO J., 29:643–654.
43.
PistilliE.E., BogdanovichS., GoncalvesM.D.et al.2011. Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. Am. J. Pathol., 178:1287–1297.
44.
RiviereC., DanosO., DouarA.M.2006. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther., 13:1300–1308.
45.
SakoD., GrinbergA.V., LiuJ.et al.2010. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J. Biol. Chem., 285:21037–21048.
46.
SchuelkeM., WagnerK.R., StolzL.E.et al.2004. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med., 350:2682–2688.
47.
SharpP.S., JeeH., WellsD.J.2011. Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. Mol. Ther., 19:165–171.
48.
SouzaT.A., ChenX., GuoY.et al.2008. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol. Endocrinol., 22:2689–2702.
49.
SpitaliP., HeemskerkH., VossenR.H.et al.2010. Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest., 90:1396–1402.
50.
TinsleyJ.M., PotterA.C., PhelpsS.R.et al.1996. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature, 384:349–353.
51.
van DeutekomJ.C., JansonA.A., GinjaarI.B.et al.2007. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med., 357:2677–2686.
52.
WagnerK.R., FleckensteinJ.L., AmatoA.A.et al.2008. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann. Neurol., 63:561–571.
53.
WelleS., MehtaS., BurgessK.2011. Effect of postdevelopmental myostatin depletion on myofibrillar protein metabolism. Am. J. Physiol Endocrinol. Metab., 300:E993–E1001.
54.
YokotaT., LuQ.L., PartridgeT.et al.2009. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann. Neurol., 65:667–676.
55.
ZhouX., WangJ.L., LuJ.et al.2010. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell, 142:531–543.
56.
ZoncuR., EfeyanA., SabatiniD.M.2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol., 12:21–35.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
